Bromocriptine is a sympatholytic dopamine D2 receptor agonist with remarkable
bioactivities. It has been used clinically as a prescription drug for more than 30 years to treat …

This paper reviews the safety data on bromocriptine administration for 1 to 10 years at daily
doses of 1.25 to 80 mg in over 1100 patients with pituitary hormone overproduction (mainly …

Objectives: Identify the mechanism of action of bromocriptine. Describe the potential adverse
effects of bromocriptine. Review the appropriate monitoring for patients receiving therapy …

CA, catecholamine; DA, dopamine (1); ΝΑ, noradrenaline, epinephrine; GAB A, gamma-
aminobutyric acid; 5-HT, 5-hydroxytryptamine, serotonin; 5-HTP, 5-hydroxytryptophan; HVA …

Bromocriptine 1, a lysergic acid derivative with a bromine atom at position 2, has been found
to have unique effects on the dopamine receptors in the pituitary and central nervous system …

Summary Bromocriptine, or 2-bromo-α-ergocryptine, is a semisynthetic ergot alkaloid. The
basis of its therapeutic application in endocrine and neurological diseases is its action as a …

Bromocriptine is an ergot alkaloid dopamine D2 receptor agonist that has been used
extensively in the past to treat hyperprolactinaemia, galactorrhoea and Parkinsonism. It is …

Importance to the field: There is a large unmet need for new therapies to treat type 2
diabetes (T2DM) which reduce fasting and postprandial glucose without increasing insulin …

Bromocriptine mesylate quick-release was approved by the Food and Drug Administration
(FDA) in May 2009, for the treatment of type 2 diabetes. Bromocriptine is thought to act on …

The absorption, distribution, and excretion of bromocriptine were studied following oral and
parenteral administration of non‐radioactive and 14C‐labelled drug in the rat. Total …